No takes yet. Share an insight, caveat, or question.
Newer reversible P2Y12 antagonists and higher-dose strategies may overcome the limitations of clopidogrel in ACS patients, though the balance between ischemic benefit and bleeding risk remains to be established in ongoing Phase 3 trials.
Jean‐Pierre Bassand (2008) conducted a review in Acute coronary syndromes (ACS). Antiplatelet therapy (prasugrel, AZD6140, clopidogrel) was evaluated. Newer antiplatelet therapies such as prasugrel and AZD6140 offer faster onset and greater platelet inhibition than clopidogrel for acute coronary syndromes, pending results from ongoing trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: